Dr Ingo Röhl

Managing Director Operations

Ingo started his career as Research Associate at the Riedel de Haën AG. He then studied Chemistry and, after completion of his Ph.D. at the University of Oldenburg, worked as Scientist at the Noxxon Pharma AG. 
Ingo joined Alnyam Europe AG in 2003 where he served as Head of Analytics and built up the analytical department. He held a position as Associate Director at the Roche Kulmbach GmbH and as Senior Director Analytics and Bioanalytics at the Axolabs Kulmbach GmbH. 
Ingo has more than 20 years of experience in the field of RNA drug development and (bio-) analytics. He has published more than 20 peer-reviewed articles and book chapters and is inventor on more than 10 patent applications. 

Dr Philipp Hadwiger

Managing Director Research 

Philipp studied Chemistry at the Technical University of Graz, Austria. After earning his doctoral degree, he started his industry career in 2000 at Ribopharma AG and held positions of increasing responsibility at Alnylam Europe AG. After Roche’s acquisition of Alnylam’s European site, Philipp served as Director of Chemistry at Roche’s Centre of Excellence for RNA Therapeutics and was promoted to Senior Director of Chemistry at Axolabs. Philipp has published 40 peer-reviewed articles and is a named inventor on more than 20 patents. 

Hermann Frings

Managing Director Finance

After studying micro- and macro-economics and law at the University of Siegen, Hermann worked in a family business in the IT sector, where he established the finance and controlling departments. He then gained extensive experience in the introduction of new ERP- and IT-systems as Head of Controlling at GoodyearDunlop. He then worked in the chemical industry for Kemira and Synthomer as CFO in stocklisted, global corporations, where he was responsible for many acquisitions, post-merger integrations and transformations. Almost 10 years ago, he  moved into the pharmaceutical industry and the private equity environment, where he was managing the growth of the API producing PharmaZell & Farmabios Group (now Axplora). Afterwards he was taking responsibility for several international acquisitions at PharmaLex Group in the pharma services sector and working very closely with the investor as CFO to ensure that the Group was well positioned for steady growth in infrastructure and all service functions. In the last 3 years he was CFO, in the meantime also as interim CEO & CCO, at Solvias AG in Switzerland, a very renowned company in the areas of CRO and CDMO and therefore has extensive experience in our business areas.